Kaplan Fox Advises DICK’s Sporting Goods, Inc. (NYSE: DKS) Investors of a Securities Class Action Deadline on November 3, 2026NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DICK’s Sporting Goods, Inc. (“Dick’s Sporting Goods” or the “Company”) (
NYSE: DKS) on behalf of investors that purchased or otherwise acquired Dick’s Sporting Goods common stock between September 8, 2025 and August 24, 2026 (the “Class Period”).
Kaplan Fox Encourages Taboola.com Ltd. (NASDAQ: TBLA) Investors Who Suffered Losses to Seek a Leadership Role Before October 20, 2026NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Taboola.com Ltd. (“Taboola.com” or the “Company”) (
NASDAQ: TBLA) on behalf of investors that purchased or otherwise acquired Taboola.com securities between May 6, 2026 and August 4, 2026 (the “Class Period”).
Meltwater launches brand campaign “Intelligence is Always in Style” starring Kim CattrallThe award-winning actress takes on the role of a brand executive, as Meltwater celebrates 25 years of helping brands navigate the changing media landscape.
Frontline Education to Preview New Vision for K–12 District Operations at AASPA 2026Company to engage school HR leaders through an interactive booth experience and two conference sessions
Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-CAdditional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life
Celestica Introduces the DS6005 Data Center Switch with Co-Packaged Optics to Enable Power-Efficient AI FabricsNew 102.4Tbps, 1.5OU fully liquid-cooled system is designed to increase bandwidth density and reduce power in OCP ORv3 deployments
STMicroelectronics announces status of common share repurchase programSTMicroelectronics announces status of common share repurchase program
Park Place Technologies Extends Microsoft Cloud Capability Across U.S. and CanadaTrusted capability expansion helps customers modernize, manage, and optimize cloud environments with one accountable partner across infrastructure and Microsoft Azure services.
Kaplan Fox Notifies Investors of Beta Bionics, Inc. (NASDAQ: BBNX) of a Securities Fraud Class Action Deadline on November 3, 2026NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).
ZJK Secures Strategic Licenses to CAMCAR Innovations’ TORX® Portfolio, Expanding Advanced Fastening SolutionsSHENZHEN, China, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ZJK Industrial Co., Ltd. (
NASDAQ: ZJK) (“ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies, today announced that its subsidiaries, Shenzhen Zhongjinke Hardware Products Co., Ltd., Zhongke Precision Components (Guangdong) Co., Ltd., Zhongjinke Precision Parts (Sichuan) Co., Ltd., ZJK Precision Components Vietnam Co., Ltd. and Inter Precision Components (Longyan) Co., Ltd. (collectively, “ZJK Entities”) have entered into a strategic licensing arrangement with CAMCAR Innovations, a global leader in engineered fastening technologies.
OSS Unveils Tamarack-G, a Next-Generation OCP/VPX Hybrid System, at AUSA 2026Disruptive rugged tactical computing platform designed to deliver 600x lower latency and 6x greater bandwidth
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026FLORHAM PARK, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced new cost-effectiveness data for VOQUEZNA® (vonoprazan), alongside additional clinical and real-world data, presented at the American College of Gastroenterology’s (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee. A new predictive cost-effectiveness analysis projected VOQUEZNA to provide meaningful economic value and be cost-effective compared with proton pump inhibitors (PPIs) for the healing and maintenance of Erosive Esophagitis or Erosive Gastroesophageal Reflux Disease (GERD) over patients’ lifetimes, with potential cost savings at net price based on clinical healing and maintenance of healing data and fewer anticipated downstream complications.
The Human Bean to Donate 100% of Food & Beverage Sales to Local Breast Cancer Causes on October 16Medford, OR, Oct. 12, 2026 (GLOBE NEWSWIRE) -- The Human Bean is once again inviting drink lovers across the United States to show up in the name of breast cancer treatment and education on Friday, October 16th. On this special day, 100% of all food and beverage sales from The Human Bean locations nationwide will be donated to local breast cancer foundations for the company's annual Coffee for a Cure giveback day.
Intrado and Mission Critical Partners Collaborate to Strengthen Cybersecurity for Public Safety AgenciesInitiative combines public safety technology expertise with specialized cybersecurity services to help agencies protect mission-critical operations, reduce risk, and maintain readiness
Rezolve Ai to Participate in the Maxim Growth Summit 2026NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Rezolve Ai (
NASDAQ: RZLV), a global leader in AI-powered commerce technology, announced that Arthur Yao, Group Chief Financial Officer, will participate in the Consumer & Lifestyle Panel at the Maxim Growth Summit 2026, presented by Maxim Group LLC, on Tuesday, October 13, 2026 at 9:00 a.m. Eastern Time.
National Pizza Month Survey: Americans Will Go to Great Lengths for the Perfect PizzaSmithfield Culinary’s Guest Check Survey dishes on topping loyalties, regional rivalries and the pizza preferences Americans refuse to compromise on.
Freshworks to Extend Freshservice into AI and Software Spend Governance with Agreement to Acquire ToriiOne context across applications, licenses, identities, and AI spend — so AI can understand and act on it, not just describe it
Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST),Westwood Salient Enhanced Energy Income ETF (WEEI) and Westwood Enhanced Income Opportunity (YLDW)DALLAS, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Westwood Holdings Group (WHG), a publicly-traded investment management boutique and wealth management firm, today announced monthly income distributions for Westwood Salient Enhanced Midstream Income ETF (
NYSE: MDST), Westwood Salient Enhanced Energy Income ETF (
NASDAQ: WEEI) and Westwood Enhanced Income Opportunity (YLDW) as shown in the table below. Part of the Westwood Income Series ETFs, these deliver income from both dividends and options premiums to help provide monthly income distributions for investors.
DFDV Continues Accumulating SOL as Treasury Growth Rises to 12% since August 12; CHAD Hits Record Highs Despite Crypto SelloffContinued purchases and organic accumulation drive approximately 12% growth in SOL holdings since the Company’s August 12 Earnings Update
Army Operational Assessment Validates Trust Automation SUADS Utility in Large-Scale Combat Operations TrainingNational Training Center assessment finds integrated C-UAS capability significantly enhanced force protection, increased survivability and enabled continuous sustainment operations under UAS threat
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous FleetsVancouver, Canada, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that Charging Robotics Ltd. (“Charging Robotics”), its 51%-owned subsidiary, has launched the next generation of its autonomous vehicle charging platform, designed for robotaxis, autonomous fleets and automated parking facilities.
Mobilicom Launches SwarmiX Family to Capitalize on Industry Shift Toward Drone Swarms & Networked Autonomous FleetsConnecting More Platforms per Mission Creates Opportunities to Scale Mobilicom’s Hardware and Cybersecurity Software Deployments
Dot Ai Completes $65 Million All-Stock Acquisition of Envoy TechnologiesWILMINGTON, DELAWARE, Oct. 12, 2026 (GLOBE NEWSWIRE) -- CID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC) (“Dot Ai” or the “Company”), today announced that it has completed the acquisition of Envoy Technologies, Inc. (“Envoy”) from BladeRanger Ltd. (TASE: BLRN) in an all-stock transaction valued at approximately $65 million, based on an agreed reference price of $6.00 per share of Dot Ai common stock. The transaction also involved Blink Charging Co. (Nasdaq: BLNK), the holder of an outstanding convertible note issued by Envoy.
Kaplan Fox & Kilsheimer LLP Reminds UWM Holdings Corporation (NYSE: UWMC) Investors of the Approaching Lead Plaintiff Deadline on October 13, 2026NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against UWM Holdings Corporation (“UWM Holdings” or the “Company”) (
NYSE: UWMC) on behalf of investors that purchased or otherwise acquired UWM Holdings securities between March 9, 2026 and August 5, 2026 (the “Class Period”).
Viva Gold to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 13thCompany invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Streamex Corp Announces GLDY Now Available for Custody by CNB Custody - a Division of Community National Bank, Further Expanding Custody Options for GLDYWINTER PARK, Fla., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex” or the “Company”) (
NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that GLDY, a non-tokenized share class of the Company’s gold-backed, yield-bearing tokenized asset, is now available for custody by CNB Custody, a division of Community National Bank holding more than $5 billion in assets under custody for over 40,000 customers. The acceptance of GLDY onto CNB Custody’s platform gives traditional finance investors, wealth managers, and advisors the infrastructure necessary to access yield-bearing gold exposure through custody channels they already use.
nCino Brings AI-Powered Guidance and Automation Together in Loan Officer Productivity Suite for MortgageSuite unifies six AI-powered capabilities inside the nCino Mortgage Point of Sale to help originators work more efficiently and spend more time with borrowers
Q3’26 Revenue $11.0 Million Up 38% Year/YearDrone, Defense and Industrial Pipeline Grows to $216 MillionLeadership Team Realigned for Drone and Defense GrowthSteve Bakos Named as Our First Chief Revenue Officer
Transaction in Own SharesTransaction in Own Shares
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryMIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (
NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating NVG-291 in individuals living with chronic cervical motor-incomplete SCI. NervGen anticipates completing enrollment in the second half of 2027 and reporting topline data in the first half of 2028.
Kaspi.kz to Announce Third Quarter & 9-Month 2026 Financial Results on 9 NovemberALMATY, Kazakhstan, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kaspi.kz (KSPI US) will report its financial results for the quarter and nine months ending September 30, 2026, on Monday, 9 November 2026. On that day, management will hold a conference call and webcast at 8.00am EST to review and discuss the company's results for the period.
Vivani Medical Announces Participation in Upcoming Investor ConferencesALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its participation in two investor conferences taking place this week in New York, New York:
World's Largest Stock Transfer Agent Computershare Begins Trading on OTCQX Best MarketNEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Computershare Limited (ASX: CPU, OTCQX: CMSQY, CMSQF), the world's largest stock transfer agent, has qualified to trade on the OTCQX® Best Market. Computershare upgraded to OTCQX from the Pink Limited™ Market.
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of GrowthThe Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027.
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac DiseaseSAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced positive top-line results from Cohort 1 (gluten challenge) of ANB033’s Phase 1b trial in celiac disease (CeD). ANB033, an investigational, subcutaneously administered CD122 antagonist, is designed to inhibit the signaling of both IL-15 and IL-2 on immune cells.
Is Marriage Still Worth It? Dr. John Delony Tackles the Question in New Book, “Building the Marriage You Want,” Now Available for PresaleNashville, Oct. 12, 2026 (GLOBE NEWSWIRE) -- “Building the Marriage You Want” by Dr. John Delony, a three-time national bestselling author and host of “The Dr. John Delony Show,” is now available for presale. Published by Ramsey Press, the book (ISBN: 9798887821382) will be released on January 26, 2027.
Beacon Therapeutics Presents Data from Pivotal VISTA Trial of Laru-zova at AAO 2026LONDON and CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics (Beacon or the Company), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, presented data from its registration-enabling VISTA trial evaluating its investigational program laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP) in a late-breaking oral presentation during Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting held October 9-12, 2026, in New Orleans, Louisiana.
MediciNova CEO Provides Shareholder UpdateLA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (
NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides shareholders an update on key findings from the recent topline results of its Phase 2 clinical trial evaluating MN-001 for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus in the following letter from CEO Yuichi Iwaki, Ph.D.
Point Funds 30,000th Homeowner, Surpassing $3 Billion in Home Equity InvestmentsPoint has doubled the number of homeowners it serves in under 18 months and now operates in five new states: Kentucky, Nebraska, Iowa, Kansas, and Mississippi
Origence named California Credit Union League’s Supplier of the YearCompany recognized for its commitment, excellence and contributions to the credit union movement
Submittable Announces Pratyush Rai as Chief Technology OfficerFormer Great Gray and Auction Technology Group CTO to lead Submittable's platform, data and AI strategy
Dmitry Shubov Consulting Advises Southeast Asian Firms on U.S. Expansion Readiness as ASEAN Digital Economy Growth AcceleratesFREMONT, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- As Southeast Asia’s digital economy continues to expand, more businesses across the region are starting to look seriously at the U.S. as their next growth market. In response, Dmitry Shubov Consulting, a startup consulting firm, has issued a strategic analysis outlining the legal and structural groundwork Southeast Asian technology and service firms should address before expanding into the U.S. The timing follows ASEAN’s 2026 Digital Economy Framework Agreement (DEFA) study, which projects the region’s digital economy could reach US$2 trillion by 2030. For many founders, interest in the U.S. market starts with growth. New customers, stronger partnerships, and a bigger commercial footprint. But making that move successfully usually depends on work happening behind the scenes first. Business structure, contracts, intellectual property, and internal documentation all play a role in whether expansion moves forward smoothly or stalls under pressure.Dmitry Shubov Consulting works with internationally focused companies on the planning needed to make cross-border growth more practical and less reactive. As more Southeast Asian businesses explore U.S. expansion, the firm is encouraging leadership teams to prepare early by looking closely at entity structure, governance, commercial agreements, and day-to-day operational readiness.That process may include choosing the right U.S. business structure, clarifying responsibilities between related entities, reviewing customer agreements, organizing IP records, and making sure the company is prepared for banking, diligence, and partnership conversations.“Many companies feel ready to grow internationally because the demand is there,” said Dmitry Shubov, founder of Dmitry Shubov Consulting. “But once expansion starts, it becomes clear very quickly whether the business has the right structure behind it. When that groundwork is done early, companies are usually in a much better position to move with confidence.”The firm notes that many delays in cross-border expansion are avoidable and often come down to preparation rather than opportunity. With more Southeast Asian companies thinking globally, market-entry readiness is becoming a more important part of growth planning. For more information, visit DmitryShubovConsulting.com.
Flyte Aviation Reports Record Preliminary Third Quarter Revenue of $2.15 Million, Up 110% Quarter Over QuarterNEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Flyte Aviation, Inc. (NYSE American: VJET), a technology-enabled private aviation company, today announced record preliminary third quarter 2026 revenue of approximately $2.15 million. This represents an increase of approximately 110%, quarter-over-quarter, compared with $1.02 million in the second quarter of 2026.
Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth RatesBERLIN, Oct. 12, 2026 (GLOBE NEWSWIRE) -- The Gates Foundation and Wellcome Leap today announced a new initiative called Uzima: A Stillbirth Prevention Program, which aims to demonstrate that stillbirth rates can be reduced by half over the next decade across select countries. Uzima will identify, validate, and scale promising innovations that can help families and health workers recognize risks earlier and respond to complications during pregnancy and childbirth. By showing what works in partnership with different health systems, the program will create a model for bringing these advances to women and babies around the world.
Airbus U740 Valkyrie Uncrewed Combat Aircraft Takes off for First European Test FlightSAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc., (
NASDAQ: KTOS) a technology company in the defense, national security and global markets, and Airbus announced the successful completion of the first flight of the “U740-Valkyrie” in Europe. This key milestone confirms that Airbus and Kratos are on track to deliver a combat-ready uncrewed Collaborative Combat Aircraft (CCA) by 2029, addressing the operational requirements of the German and other European Armed Forces.
DHT Holdings, Inc. Business UpdateHAMILTON, BERMUDA, October 12, 2026 – DHT Holdings, Inc. (
NYSE:DHT) (“DHT” or the “Company”) today provides the following business update:
BROAD ARROW ZOUTE CONCOURS SALE BECOMES THE HIGHEST GROSSING COLLECTOR CAR AUCTION IN BELGIAN HISTORYBroad Arrow celebrating success of second annual Zoute Concours Auction in collaboration with Zoute Grand Prix with €34.6 million in total sales and 91 percent sell-through rate | 2015 Ferrari LaFerrari the most valuable car ever sold at auction in Belgium with a final price of €5.181.250 | 2015 Porsche 918 Spyder Weissach Package and 2015 McLaren P1 complete ‘Holy Trinity’ sale | Unique BMW M5 W10 prototype driven by Dr. Ferdinand Piëch breaks world record for price of an E39 BMW at €411.250 | Complete results from Broad Arrow’s Zoute Concours Auction now available at broadarrowauctions.com
ProLogium and Rimac Technology Advance Next-Generation EV Battery DevelopmentConcept mockup to be showcased at the 2026 Paris Motor Show, with functional battery segment development planned as the next phase of cell and system integration work
Kosmos Energy to Host Third Quarter 2026 Results and Webcast on November 2, 2026DALLAS, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kosmos Energy (NYSE/LSE: KOS) announced today the following schedule for its third quarter 2026 results:
Gibraltar and ADI Foundation Explore Landmark Multi-Currency Stablecoin Consortium in GibraltarGIBRALTAR and ABU DHABI, United Arab Emirates, Oct. 12, 2026 (GLOBE NEWSWIRE) -- His Majesty’s Government of Gibraltar and ADI Foundation have signed a Memorandum of Understanding to explore establishing a multi-currency stablecoin consortium, marking a significant step in building regulated digital financial infrastructure connecting international markets.
GTCFX-PR 5-GTCPrime Signs Off From iFX Expo Hong Kong 2026 After Two Days of Insight and ConnectionDUBAI, United Arab Emirates, Oct. 12, 2026 (GLOBE NEWSWIRE) -- GTCPrime has closed out its participation as Gold Sponsor at iFX Expo Hong Kong 2026, held on October 8-9 at the Hong Kong Convention and Exhibition Centre. Over the two days, the GTCPrime team welcomed clients, partners, and industry peers at Booth 14 to discuss market developments and the changing needs of investors across Asia-Pacific.
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesityTwo oral presentations at AHA Hypertension 2026 demonstrate the pronounced efficacy of aprocitentan in two groups of patients with notoriously difficult to control hypertension from the PRECISION study: patients with obesity and patients across the cardiovascular-kidney-metabolic (CKM) continuum.
VALLOUREC AWARDED MAJOR CONTRACT BY TOTALENERGIES FOR THE ABSHERON GAS FIELD IN AZERBAIJANVALLOUREC AWARDED MAJOR CONTRACT BY TOTALENERGIES FOR THE ABSHERON GAS FIELD IN AZERBAIJAN
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in ChinaBEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for the treatment of autoimmune diseases, including inflammatory bowel disease (IBD). ICP-B161 is InnoCare’s fifth novel drug candidate to enter clinical development in 2026.
